Literature DB >> 11733470

Tetracycline delivery from fibrin controls peritoneal infection without measurable systemic antibiotic.

C J Woolverton1, J A Fulton, S J Salstrom, J Hayslip, N A Haller, M L Wildroudt, M MacPhee.   

Abstract

The addition of antibiotics to an adhesive haemostat results in an ideal system for the treatment of a localized infectious disease. Fibrin sealant (FS) is a biocompatible, resorbable, adherent haemostat that can deliver antibiotics. Previous use of fibrin to deliver antibiotics resulted in rapid release and limited bioactivity. We have reported previously that poorly soluble antibiotics significantly retard release from FS, resulting in extended delivery in vitro, and overcome antibiotic-resistant infection. We now report that localized antibiotic delivery from FS controls peritoneal infection without measurable systemic antibiotic. Rats and mice were implanted with preformed FS discs containing tetracycline free-base to evaluate control of peritoneal sepsis and to measure serum tetracycline levels. Infection was initiated with Staphylococcus aureus. Morbidity and mortality were evaluated for 14 days. Serum was isolated from jugular vein blood with subsequent evaluation for antimicrobial activity. Mice prophylactically treated with FS-tetracycline (FS-TET) 500 mg/kg 2 days before infection cleared the S. aureus infection, resulting in 100% survival. Mice treated with FS-TET 500 mg/kg 7 days before infection survived. Mice treated with FS-TET 1750 mg/kg 35 days before infection also survived. Rats treated with FS-TET 500 mg/kg had undetectable serum tetracycline levels, whereas in vitro release of tetracycline from FS-TET pellets in rat serum was readily detected. We conclude that fibrin is an excellent vehicle for extended delivery of low solubility tetracycline. Tetracycline delivered from FS is an appropriate chemotherapy for S. aureus peritonitis. FS-TET controls localized infection without a measurable concentration of systemic tetracycline.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11733470     DOI: 10.1093/jac/48.6.861

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  8 in total

1.  Cloxacillin concentrations in serum, subcutaneous fat, and muscle in patients with chronic critical limb ischemia.

Authors:  T B Jonsson; T K Nilsson; L H Breimer; J Schneede; B Arfvidsson; L Norgren
Journal:  Eur J Clin Pharmacol       Date:  2014-05-27       Impact factor: 2.953

2.  The use of antibiotic-impregnated fibrin sealant for the prevention of surgical site infection associated with spinal instrumentation.

Authors:  Katsuhiro Tofuku; Hiroaki Koga; Mitsuhiro Yanase; Setsuro Komiya
Journal:  Eur Spine J       Date:  2012-07-22       Impact factor: 3.134

3.  Use of fibrin sealants for the localized, controlled release of cefazolin.

Authors:  Stephen Tredwell; John K Jackson; Donald Hamilton; Vivian Lee; Helen M Burt
Journal:  Can J Surg       Date:  2006-10       Impact factor: 2.089

4.  Comprehensive evaluation of fibrin glue as a local drug-delivery system-efficacy and safety of sustained release of vancomycin by fibrin glue against local methicillin-resistant Staphylococcus aureus infection.

Authors:  Shinichi Ozaki; Aya Saito; Hidemasa Nakaminami; Minoru Ono; Norihisa Noguchi; Noboru Motomura
Journal:  J Artif Organs       Date:  2013-12-01       Impact factor: 1.731

5.  Sustained-released mixture of vascular endothelial growth factor 165 and fibrin glue strengthens healing of ileal anastomoses in a rabbit model with intraperitoneal infection.

Authors:  Zhanwu Li; Wenjun Wang; Xiaozhou Wang; Lei Jiang; Fengyi Wang; Qiang Liu
Journal:  Ann Surg Treat Res       Date:  2017-08-30       Impact factor: 1.859

6.  Antibacterial activity of antipsychotic agents, their association with lipid nanocapsules and its impact on the properties of the nanocarriers and on antibacterial activity.

Authors:  Hassan Nehme; Patrick Saulnier; Alyaa A Ramadan; Viviane Cassisa; Catherine Guillet; Matthieu Eveillard; Anita Umerska
Journal:  PLoS One       Date:  2018-01-03       Impact factor: 3.240

7.  Improved anti-tumor efficacy via combination of oxaliplatin and fibrin glue in colorectal cancer.

Authors:  Yuzhu Hu; Ting Yu; Xiaoxiao Liu; Yihong He; Lihong Deng; Jiajuan Guo; Yuanqi Hua; Ting Luo; Xiang Gao
Journal:  Oncotarget       Date:  2017-12-20

8.  Antifungal efficacy of amphotericin B encapsulated fibrin microsphere for treating Cryptococcus neoformans infection in Swiss albino mice.

Authors:  Azmat Ali Khan; Mumtaz Jabeen; Amer M Alanazi; Abdul Arif Khan
Journal:  Braz J Infect Dis       Date:  2016-06-11       Impact factor: 3.257

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.